Disclosure of Amyloid Status for Risk of Alzheimer Disease to Cognitively Normal Research Participants With Subjective Cognitive Decline: A Longitudinal Study.

Aged Alzheimer Disease / diagnosis Amyloid beta-Peptides / metabolism Anxiety / psychology Cognitive Dysfunction / diagnostic imaging Depression / psychology Disclosure Female Healthy Volunteers / statistics & numerical data Humans Longitudinal Studies Male
Alzheimer disease amyloid imaging disclosure ethics subjective cognitive decline

Journal

American journal of Alzheimer's disease and other dementias
ISSN: 1938-2731
Titre abrégé: Am J Alzheimers Dis Other Demen
Pays: United States
ID NLM: 101082834

Informations de publication

Date de publication:
Historique:
entrez: 14 2 2020
pubmed: 14 2 2020
medline: 15 12 2020
Statut: ppublish

Résumé

This study aimed to investigate the long-term impacts of disclosing amyloid status for a risk of Alzheimer disease (AD) to cognitively normal research participants with subjective cognitive decline (SCD), which represents an initial manifestation of AD. Forty-two participants were classified as the amyloid-positive (

Identifiants

DOI: 10.1177/1533317520904551 PMID: 32052640
pubmed: 32052640
doi: 10.1177/1533317520904551
doi:

Substances chimiques

Amyloid beta-Peptides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1533317520904551

Auteurs

Taisei Wake (T)

Department of Psychiatry, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
ORCID: 0000-0001-6032-9500

Hajime Tabuchi (H)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
ORCID: 0000-0002-2321-711X

Kei Funaki (K)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Daisuke Ito (D)

Department of Neurology, Keio University School of Medicine, Tokyo, Japan.

Bun Yamagata (B)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Takahito Yoshizaki (T)

Department of Neurology, Keio University School of Medicine, Tokyo, Japan.

Tadaki Nakahara (T)

Department of Diagnostic Radiology, Keio University School of Medicine, Tokyo, Japan.

Masahiro Jinzaki (M)

Department of Diagnostic Radiology, Keio University School of Medicine, Tokyo, Japan.

Haruo Yoshimasu (H)

Department of Psychiatry, Saitama Medical Center, Saitama Medical University, Saitama, Japan.

Iori Tanahashi (I)

Department of Psychiatry, Saitama Medical Center, Saitama Medical University, Saitama, Japan.

Hiroumi Shimazaki (H)

Department of Psychiatry, Saitama Medical Center, Saitama Medical University, Saitama, Japan.

Masaru Mimura (M)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Disclosure of Amyloid Status for Risk of...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › Disclosure of Amyloid Status for Risk of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Peptides bêta-amyloïdes › Disclosure of Amyloid Status for Risk of...
questionsmedicales.fr › Comportement et mécanismes comportementaux › Émotions › Anxiété › Disclosure of Amyloid Status for Risk of...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Troubles de la cognition › Dysfonctionnement cognitif › Disclosure of Amyloid Status for Risk of...
questionsmedicales.fr › Comportement et mécanismes comportementaux › Émotions › Dépression › Disclosure of Amyloid Status for Risk of...
questionsmedicales.fr › Sciences de l'information › Communication › Divulgation › Disclosure of Amyloid Status for Risk of...
questionsmedicales.fr › Personnes › Bénévoles › Volontaires sains › Disclosure of Amyloid Status for Risk of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Disclosure of Amyloid Status for Risk of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études longitudinales › Disclosure of Amyloid Status for Risk of...